Verona Culture Company

Dr. Kenneth Newman Ph.D., MBA, M.D. has been the Chief Medical Officer at Verona Pharma plc since January 1, 2015. Dr. Newman served as the Chief Medical Advisor of Acton Pharmaceuticals, Inc. Dr. Newman served as Executive Vice President and Chief Medical Officer of Acton Pharmaceuticals, Inc from 2010 and 2013, where he was responsible for the clinical development and regulatory submission of two respiratory products that were subsequently approved by the FDA. Dr. Newman is an experienced pharmaceutical and biotechnology industry executive with extensive leadership experience in clinical development, including a number of orally inhaled drugs for the treatment of respiratory disease. Dr. Newman served as head of Medical Affairs at Boehringer-Ingelheim. From 2006 to 2009, Dr. Newman was Vice President , Medical Affairs at Boehringer Ingelheim, where he oversaw the Medical Affairs Department, which comprised of a number of therapeutics areas, including respiratory. Dr. Newman served as the Chairman of Scientific Advisory Board and Member of Scientific Advisory Board of Acton Pharmaceuticals, Inc. since May 2010. Dr. Newman is a board certified Pulmonologist, asthma expert and pharmaceutical development veteran, who led respiratory clinical development at Forest Laboratories. He served as the Chief Development Officer and Head of Global Clinical Development at Mesoblast Inc. From 1997 to 2006, Dr. Newman held a number of positions of increasing seniority within the Clinical Development and Medical Affairs Departments at Forest Laboratories (now Actavis ) and served as Executive Director of Clinical Development. Dr. Newman began his professional career as an attending physician at the National Jewish Medical and Research Center, Denver, Colorado and then the University of Cincinnati, Ohio. He was awarded an MBA from University of Cincinnati in 1998. He holds MD from The University of Texas System. He holds BS from University of Cincinnati.

Mr. Piers John Morgan, MA, ACA has been Chief Financial Officer at Verona Pharma plc since September 26, 2016. Mr. Morgan has 25 years of financial experience, predominantly in the life sciences sector, having held both corporate and advisory senior positions. He has extensive financing expertise, having led IPOs on AIM, NASDAQ and Euronext Paris as well as having completed more than 120 transactions. He was the Chief Executive Officer of C4X Discovery plc, where he led the company's successful IPO on London's AIM market in 2014. Prior to this he co-founded uniQure, where he spent five years as Chief Financial Officer leading a number of equity and debt transactions, including the company's $92 million IPO on NASDAQ in 2014. He has also held Chief Financial Officer roles at London listed Phytopharm, Paris listed BioAlliance Pharma and Arrow Therapeutics. He was Non-Exec Chairman of Trino Therapeutics. He is a Non-executive Director at Quethera Ltd, From 1997 to 2000 he was a Director in the Ernst and Young Life Sciences M& A practice, where he founded the Life Sciences M&A team. Prior to this he spent five years as an Assistant Director at Close Brothers Corporate Finance. Mr. Morgan is a Chartered Accountant.

Dr. Peter Spargo, also known as Pete, Ph.D., has been Senior Vice President of CMC at Verona Pharma plc since June 23, 2017. Dr. Spargo served as Senior Vice President of Chemistry, Manufacturing & Controls of Spinifex Pharmaceuticals Inc. since February 2015. Dr. Spargo serves as Senior Vice President of CMC at Spinifex Pharmaceuticals Pty Limited. He served as Head of CMC and Manufacturing at Verona Pharma plc until June 23, 2017 and served as its Senior Vice President of Chemistry, Manufacturing & Controls since May 2014. He has been involved in pharmaceutical research and development throughout an international career spanning over 25 years. Dr. Spargo served as Senior Vice President of Chemistry Manufacturing & Controls at Creabilis SA since October 11, 2011. Dr. Spargo served as Managing Director of Scientific Update LLP since January 2006, where he joined it in September 2003. He served as Group Director of Head of European Chemical Research and Development for Pfizer Global R & D. He is responsible for Pfizer's Worldwide Pharmaceutical Sciences Veterinary Medicine portfolio, encompassing formulation, analytical and chemical development activities. Dr. Spargo served as Senior Vice President, Chemistry Manufacturing & Controls of Novexel SA and also served as its Vice President, Chemistry Manufacturing & Controls. He served as Scientific Advisor of Prosonix Limited. Dr. Spargo is a highly experienced process and manufacturing chemist. Dr. Spargo acts as an international consultant to a number of pharmaceutical companies and also as an expert witness in patent litigation. In addition to teaching the Chemical Development course, he has also developed new courses in Green Chemistry and Microwave Chemistry. Dr. Spargo is Pharmaceutical Sciences Team Leader for Stronghold/Revolution(TM) (selamectin), successfully taken from discovery through to commercialization ; also chemical development line management responsibility for eletriptan and Chairman of multidisciplinary clinical development candidate management teams in wound healing. Dr. Spargo is a fellow of the Royal Society of Chemistry and has authored numerous scientific papers and patents. He holds a PhD in Synthetic Organic Chemistry from Cambridge University and completed Post-Doctoral research at Columbia University.

Ms. Claire Louise Poll, B.A., B Juris, LLB, ASIA, has been Legal Counsel of Verona Pharma plc since September 2016. Ms. Poll has been General Counsel of Verona Pharma plc since November 21, 2016. Ms. Poll served as Legal Counsel of Verona Pharma plc since October 10, 2016 until November 21, 2016. Ms. Poll served as a Director of Corporate Development of Inniarsat. At Inniarsat, Ms. Poll was responsible for group strategy, mergers and acquisitions and advising the Inmarsat board on investing in new satellite technology. She has 12 years experience as a corporate executive for start-up and mature technology companies internationally. Prior to Inmarsat, she held corporate development and legal roles in the telecommunications, software and food ingredients industries. Ms. Poll has been an Executive Director of Australian Development Capital Fund since March 11, 2005. She served as Executive Director of Verona Pharma plc from September 18, 2006 to September 10, 2015. She serves as a Non-Executive Director of Cool Energy Pty Ltd. She serves as Independent Non-Executive Director at Alexium International Group Ltd. Ms. Poll served as a Director of Ming Resources Plc. She served as an Executive Director of Energy Ventures Ltd. from March 11, 2005 to April, 2006. and as its Director from August 18, 2004 to March 11, 2005. She served as a Director of Matra Petroleum Plc until April 11, 2006 and TranServ Australia Ltd. from July, 2006 to November 29, 2007. Ms. Poll holds the degrees of Bachelor of Arts, Bachelor of Jurisprudence and Bachelor of Law from the University of Western Australia and is an Associate of the Securities Institute of Australia.